Note: This variant has not been sufficiently evaluated by a GET-Evidence editor.
To be considered sufficiently evaluated a variant must have both "variant evidence" and "clinical importance" scores filled in.
Please help improve GET-Evidence by evaluating evidence for this variant!
You are viewing an old version of this page that was saved on April 5, 2010 at 11:08am by Madeleine Ball.
Edited in this revision:
Insufficiently evaluated not reviewed
(The "insufficiently evaluated" qualifier is assigned automatically based on the above evidence and importance scores.)
Summary of published research, and additional commentary
Xu B, Tong N, Li JM, Zhang ZD, Wu HF. ELAC2 polymorphisms and prostate cancer
risk: a meta-analysis based on 18 case-control studies. Prostate Cancer Prostatic
Dis. 2010 Mar 16. [Epub ahead of print] PubMed PMID: 20231859.
huE80E3D - CGI sample GS00253-DNA_D01_200_37
hom A @ chr17:12915009